AbbVie Inc. (ETR:4AB)
Germany · Delayed Price · Currency is EUR | Market Cap | 347.06B |
| Revenue (ttm) | 50.83B |
| Net Income (ttm) | 2.00B |
| Shares Out | n/a |
| EPS (ttm) | 1.13 |
| PE Ratio | 173.43 |
| Forward PE | 16.64 |
| Dividend | 5.86 (2.99%) |
| Ex-Dividend Date | Oct 15, 2025 |
| Volume | 288 |
| Average Volume | 377 |
| Open | 196.00 |
| Previous Close | 196.00 |
| Day's Range | 195.20 - 197.00 |
| 52-Week Range | 147.60 - 207.00 |
| Beta | 0.35 |
| RSI | 48.71 |
| Earnings Date | Jan 30, 2026 |
About AbbVie
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer... [Read more]
Financial Performance
In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.
Financial numbers in USD Financial StatementsNews
Best Dividend Aristocrats For December 2025
The ProShares S&P 500 Dividend Aristocrats ETF (NOBL) has underperformed the SPDR S&P 500 ETF (SPY) year-to-date, but November shows a reversal. Several Dividend Aristocrats, including CAH, CAT, CHRW,...
SKYRIZI® (risankizumab) Receives Positive Reimbursement Recommendation by Canada's Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance
MONTREAL, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Today, AbbVie (NYSE: ABBV) has announced two positive updates for Canadians living with ulcerative colitis (UC).
8 Dividend Stocks Every Investor Should Consider
Dividend investing isn't just about yield -- payout ratio and growth potential matter too. Several of these companies have increased dividends for decades without interruption.
AbbVie and adMare BioInnovations Foster Life Sciences Innovation with the Launch of the AbbVie Biotech Innovators Award in Quebec
MONTREAL, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Today, AbbVie (NYSE: ABBV), jointly with the adMare BioInnovations, announced the launch of the AbbVie Biotech Innovators Award, a prize to help foster inno...
AbbVie to Present at the Piper Sandler 37th Annual Healthcare Conference
NORTH CHICAGO, Ill. , Nov. 24, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025.
5 Dividend Stocks to Hold for the Next 10 Years
These dividend stocks represent the communications services, energy, financial services, healthcare, and real estate sectors. All of them have attractive dividend yields.
The Zacks Analyst Blog JPMorgan, Netflix, AbbVie and Ohio Valley Banc
JPM shows solid operational strength as analysts highlight its NII outlook, fee pressures and expense trajectory through 2027.
Top Research Reports for JPMorgan Chase, Netflix & AbbVie
JPMorgan's year-to-date gains, NII growth outlook and investment banking pipeline headline today's standout Zacks research picks.
Unpacking the Latest Options Trading Trends in AbbVie
Financial giants have made a conspicuous bearish move on AbbVie. Our analysis of options history for AbbVie (NYSE: ABBV) revealed 9 unusual trades. Delving into the details, we found 11% of traders w...
If You Invested $100 In AbbVie Stock 10 Years Ago, You Would Have This Much Today
AbbVie (NYSE: ABBV) has outperformed the market over the past 10 years by 2.1% on an annualized basis producing an average annual return of 14.31%. Currently, AbbVie has a market capitalization of $4...
HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?
Most of the health care sector's headlines are dominated by Big Pharma giants. Legacy companies, including AbbVie (NYSE: ABBV), Eli Lilly (NYSE: LLY), Pfizer (NYSE: PFE), and Merck (NYSE: MRK)—and the...
AbbVie Stock Rebounds After Q3 Dip: Time to Buy, Hold or Sell?
ABBV rebounds after its Q3 dip as strong immunology and neuroscience growth offset Humira erosion and aesthetics weakness.
FDA Greenlights AbbVie And Genmab's EPKINLY Combo For Relapsed Or Refractory Follicular Lymphoma
(RTTNews) - AbbVie Inc. (ABBV) announced that the FDA has approved EPKINLY in combination with rituximab and lenalidomide for the treatment of adult patients with relapsed or refractory follicular lym...
FDA Approves AbbVie's EPKINLY for Follicular Lymphoma Treatment
FDA Approves AbbVie's EPKINLY for Follicular Lymphoma Treatment
AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma
- EPKINLY plus rituximab and lenalidomide (EPKINLY + R2) is now the first and only bispecific antibody combination therapy available for patients with relapsed or refractory follicular lymphoma aft...
FDA Expands Approval for AbbVie's (ABBV) Epkinly in Lymphoma Treatment
FDA Expands Approval for AbbVie's (ABBV) Epkinly in Lymphoma Treatment
AbbVie, Genmab win FDA label expansion for Epkinly in follicular lymphoma
It's Best Time In 10 Years To Lock In Income: Our Picks
Investors can now access 4–7% from top-quality REITs, 3.5%+ from dividend ETFs, and 6%+ from midstream infrastructure — without taking on excessive risk. While the S&P 500 is up ~110% since 2020, 70–8...
Global drugmakers rush to boost US presence as tariff threat looms
Global drugmakers are rushing to boost U.S. manufacturing and inventory as the Trump administration weighs a 100% tariff on imported branded and patented drugs.
A Look Into AbbVie Inc's Price Over Earnings
In the current session, the stock is trading at $233.57, after a 0.52% spike. Over the past month, AbbVie Inc. (NYSE: ABBV) stock increased by 0.94% , and in the past year, by 40.22% . With performan...
AbbVie (ABBV) Gains Health Canada Approval for New Lupron Depot Dosage
AbbVie (ABBV) Gains Health Canada Approval for New Lupron Depot Dosage
AbbVie: New 6-month 45mg LUPRON DEPOT Strength Receives Health Canada Approval
(RTTNews) - AbbVie (ABBV) announced that a new 6-month 45mg LUPRON DEPOT, or leuprolide acetate for extended-release injectable suspension, strength has received Health Canada approval for the treatme...
AbbVie Stock Falls 4% -- What Investors Need to Know
AbbVie's third-quarter results were pretty strong, and the company increased its guidance. It was not enough to impress the market, which apparently expected more from the drugmaker.
Guru Fundamental Report for ABBV
Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our Multi-Factor Investor model based on the published strategy of Pim v...
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever.
AbbVie is a Dividend King with a bright future. Enbridge offers an especially dependable dividend.